QED Therapeutics is dedicated to the development of our investigational candidate, infigratinib. A selective, tyrosine kinase inhibitor, infigratinib is under investigation for FGFR-driven cholangiocarcinoma, metastatic urothelial carcinoma, as well as studies in achondroplasia. Future studies will investigate infigratinib for additional FGFR-driven tumor types and rare disorders.